Glioblastoma (GBM) is the most common and. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients
|
|
- Doris Dalton
- 5 years ago
- Views:
Transcription
1 CLINICAL ARTICLE J Neurosurg 127: , 2017 Bone marrow response as a potential biomarker of outcomes in glioblastoma patients *Eugene J. Vaios, AB, 1,5 Brian V. Nahed, MD, MSc, 1,5 Alona Muzikansky, MA, 2 Amir T. Fathi, MD, 1,3 and Jorg Dietrich, MD, PhD 1,4 1 Harvard Medical School; and Departments of 2 Biostatistics, 3 Hematology-Oncology, 4 Neuro-Oncology, and 5 Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts OBJECTIVE Glioblastoma (GBM) is a highly aggressive malignancy that requires a multidisciplinary therapeutic approach of surgery, chemotherapy, and radiation therapy, but therapy is frequently limited by side effects. The most common adverse effect of chemotherapy with temozolomide (TMZ) is myelosuppression. It remains unclear whether the degree of bone-marrow suppression might serve as a biomarker for treatment outcome. The aim of the current study was to investigate whether the degree of bone-marrow toxicity in patients treated with TMZ correlates with overall survival (OS) and MRI-based time to progression (progression-free survival [PFS]). METHODS Complete blood counts and clinical and imaging information were collected retrospectively from 86 cases involving GBM patients who had completed both radiation therapy and at least 6 monthly cycles of chemotherapy with TMZ. RESULTS Using a multivariate Cox proportional hazard model, it was observed that MGMT promoter methylation, wild-type EGFR, younger patient age at diagnosis, and treatment-induced decreases in white blood cell counts were associated with improved OS. The 2-year survival rate was 25% and 58% for patients with increases and decreases, respectively, in white blood cell counts from baseline over 6 months of TMZ treatment. Consistent with the literature, IDH mutation and MGMT promoter methylation were associated with better PFS and OS. IDH mutation and MGMT promoter methylation were not correlated with changes in peripheral red blood cell or white blood cell counts. CONCLUSIONS Decreases in white blood cell counts might serve as a potential biomarker for OS and PFS in malignant glioma patients treated with radiation therapy and TMZ. It remains unclear whether treatment-induced changes in white blood cell counts correlate with drug-induced antitumor activity or represent an independent factor of the altered local and systemic tumor environment. Additional studies will be needed to determine dose dependence for chemotherapy based upon peripheral blood counts. KEY WORDS glioblastoma; temozolomide; bone marrow; biomarker; overall survival; oncology Glioblastoma (GBM) is the most common and most aggressive primary brain tumor, with few therapeutic advances over the last 20 years. 1 The standard of care includes surgery with a goal of maximal safe resection, followed by a combination of radiation and chemotherapy. 16 Chemoradiation includes radiotherapy 5 days per week over 6 weeks in combination with daily temozolomide (TMZ), followed by at least 6 monthly cycles of TMZ administered on 5 consecutive days per 28-day cycle. 8,16 Patients may continue on TMZ for up to 12 months at some institutions unless there are intolerable side effects such as myelosuppression. Despite standard ABBREVIATIONS EGFR = epidermal growth factor receptor; GBM = glioblastoma; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide. SUBMITTED March 18, ACCEPTED July 25, INCLUDE WHEN CITING Published online October 14, 2016; DOI: / JNS * Drs. Nahed and Dietrich contributed equally to this work. 132 AANS, 2017
2 Bone marrow response as a potential biomarker treatment, GBM remains incurable, with a median survival of less than 19 months and only a 30% probability of survival 2 years after diagnosis. 1,19 The genetic heterogeneity of GBM and the emergence of various resistance mechanisms are proposed limitations of standardized therapies. 1,18 However, MGMT promoter methylation and IDH1 mutation have been identified in genome-wide association studies as robust genetic markers for improved clinical outcomes in patients treated with standard chemoradiation. 1,18 While IDH status is considered an independent biomarker for clinical outcomes, MGMT promoter methylation is associated with improved response to TMZ and radiation and thus serves as a predictive biomarker of more favorable treatment outcomes. This observed relationship between the molecular-genetic tumor signature and treatment response has elevated the importance of noninvasive biomarkers that enable realtime selection and adjustment of personalized therapies. The unique role of the local and systemic tumor environment is increasingly recognized in overall tumor biology and treatment outcome. 18,23 The identification of a peripheral biomarker for treatment response and overall survival (OS) would improve patient management and perhaps alter chemotherapy (e.g., TMZ) dosing protocols, which currently do not account for individual pharmacogenetics, pharmacokinetics, or pharmacodynamics. 2 The use of circulating blood counts as a marker of drug activity and clinical outcomes is an emerging area of investigation. The current understanding of the effect of chemotherapeutic agents suggests that greater toxicity to various organ systems, such as the bone marrow, might reflect increased potency and, conversely, be associated with a more favorable antitumor profile. 11,12 For instance, in patients with renal cell carcinoma, leukopenia induced by the tyrosine kinase inhibitor sunitinib was identified as an independent and prognostic marker for improved response rate and progression-free survival (PFS). 4 This finding was further supported by work from Zhu et al., 24 suggesting that sunitinib-induced decreases in neutrophils, monocytes, and platelets were associated with improved progression and survival outcomes in patients with hepatocellular carcinoma. TMZ therapy, in combination with radiotherapy, significantly improves OS in GBM patients. 15 However, dosing is based solely on patient body surface area and does not account for variability in resistance mechanisms and drug metabolism, raising the possibility that some patients may be dosed subtherapeutically. Inadequate dosing may partially contribute to the observed resistance to cytotoxic treatment and ultimately tumor recurrence. One of the most common adverse effects of chemotherapy with TMZ is myelosuppression, including thrombocytopenia and leukopenia. It remains unclear whether patients who do not show a notable decrease in blood counts in response to TMZ are treated subtherapeutically. Therefore, we hypothesized that changes in circulating blood counts may be predictive of clinical outcomes, with alterations in blood counts indicative of myelosuppression being associated with improved OS and PFS. Methods We conducted a retrospective, chart-review analysis of clinical and demographic data from patients who previously underwent surgery and treatment for primary GBM at the Massachusetts General Hospital between 2007 and Patient data were obtained from a Massachusetts General Hospital institutional database. This time interval allowed enough time for diagnosis and to follow a complete blood count throughout the patient s disease course. This study received institutional review board approval from Massachusetts General Hospital for all activities. Eligibility All patients were treated at the Massachusetts General Hospital and met the following eligibility criteria: newly diagnosed with GBM (WHO Grade IV) between January 1, 2007, and July 30, 2014; 18 years of age or older at the time of diagnosis; surgical biopsy/resection after initial presentation; and treatment with at least 6 cycles of monthly TMZ. Patients who did not complete 6 months of TMZ therapy for any reason were excluded from the study. Variables Descriptive information, including age, sex, and steroid use, was collected. Steroid use was defined as exposure to steroids (e.g., dexamethasone) at any given time during the course of chemotherapy. Genetic information including chromosomal abnormalities, point mutations, and gene methylation was recorded. This included known prognostic markers for gliomas such as epidermal growth factor receptor (EGFR) amplification, MGMT promoter methylation, IDH mutation, and 1p/19q co-deletion. The genetic characteristics of the sample are reported as the percentage of those patients for whom that genetic variable was tested. Absolute peripheral blood platelet, red blood cell, white blood cell, eosinophil, basophil, lymphocyte, neutrophil, and monocyte count measurements were recorded at a maximum of 15 discrete time points during the course of treatment. Time points included before surgery, after surgery, before chemoradiation, and before each monthly TMZ treatment cycle. PFS and OS were also assessed. Statistics The primary outcome measure was OS, which was defined as the length of time from the date of initial diagnosis to time of death or last date known to be alive for those who were censored. The secondary outcome measure was PFS, which was defined as the length of time from initial diagnosis to the time of first progression based on radiology report and clinician notes indicating a switch in therapy or last date known to be progression free for censored patients. The effect of changes in peripheral blood counts on clinical outcomes was assessed during the interval between baseline measurement (before chemoradiation) and Cycle 6 of monthly TMZ, as this time interval had the greatest sample size and was controlled for the immunosuppressive effect of steroid use during surgery and chemoradiation. Baseline and 6-month blood counts were 133
3 E. J. Vaios et al. performed closest to the time of chemoradiation or TMZ initiation, but no earlier than 2 weeks prior. Changes in blood counts are reported as the percentage change from baseline to Cycle 6 of monthly TMZ. Genetic variables known to be strong prognostic markers were compared with clinical outcomes using logistic regression or Pearson s chi-square test. Spearman or Pearson correlation coefficients were estimated to measure the relation between baseline demographic variables and clinical outcome measures. Wilcoxon rank-sum tests and Kruskal-Wallis tests by ranks were used to examine differences in mean blood count changes between groups of patients stratified by IDH mutation and MGMT promoter methylation. Univariate and multivariate Cox proportional hazards models were used to evaluate variables for association with PFS and OS. Variables were chosen for multivariate analysis using the backward selection method based on statistical significance in univariate analysis. Percentage changes from baseline in white blood cell and red blood cell counts were included in the multivariate model as dichotomized variables, indicating either an increase or a decrease in that blood count from baseline. IDH mutation was excluded from the multivariate analysis due to a sample size less than 10. A Wilcoxon rank-sum test was performed to assess the association between changes in neutrophils and steroid use. Neutrophil counts at Cycle 6 of TMZ were compared between patients with and without steroid treatment using a 2-sample t-test. Changes in neutrophil counts were excluded from the multivariate analysis as they were confounded by steroid use. Survival probabilities were compared between patient groups, stratified by the dichotomous white blood cell variable, using the log-rank test. In subgroup analysis, patients with a decreased peripheral white blood cell count from baseline were subdivided into groups based on the degree of change, using either quartiles or the median decrease. Here too the log-rank test was used to compare survival curves between these patient subgroups. All reported p values were 2-sided, and statistical significance was considered as p < Results Descriptive Data Analysis In total, 86 patients diagnosed with GBM were included in this study. Their median age at diagnosis was 55 years; 32 patients (37%) were women and 54 (63%) were men. Nineteen patients (22%) were still alive at the time of data cutoff for analysis. The median OS for the entire group was 800 days, and the median PFS was 453 days. Baseline and 6-month peripheral blood counts are listed in Table 1. Mutation frequencies in the patient cohort are reported in Table 2. Univariate and Multivariate Analysis of Biomarker Impact on OS By univariate analysis, MGMT promoter methylation and IDH mutation were associated with better OS and PFS, consistent with the literature (Table 3 and Supplemental Table 1A). EGFR amplification, changes in neutrophil counts, changes in peripheral red and white blood cell parameters, steroid use, and patient age at diagnosis were also associated with OS (Table 3). As predicted, patients receiving steroids during TMZ therapy had worse OS, with a 2-year survival rate of 51% compared with 71% in patients who were not treated with steroids (p = ). Additionally, changes in neutrophil counts differed between patients with and without steroid use (p = ), and patients receiving steroids had significantly greater neutrophil counts at 6 months of TMZ compared with those who never received steroids (p = ). Changes in neutrophil counts were not associated with OS in patients who never received steroids (p = 0.300). On multivariate analysis, MGMT promoter methylation, a decreased white blood cell count from baseline, and wild-type EGFR status (i.e., EGFR not amplified) were significantly associated with improved OS (Table 4). These associations remained significant on multivariate analysis that incorporated patient age and steroid use, despite our observation that steroid use was associated with increased white blood cells counts (p = ). On subgroup analysis, decreases in white blood cell counts remained associated with improved OS with hazard ratios of (p = 0.053) and (p = 0.066) in patients with and without steroid use. Association of MGMT and IDH With Alterations in Circulating Blood Cell Counts MGMT promoter methylation and IDH1 mutation are known to be robust prognostic markers for OS in GBM patients. 1,18 Regarding the association of these genetic markers with alterations in circulating biomarkers that were significant on univariate analysis, we report that MGMT promoter methylation was not correlated with changes in peripheral red blood cell or white blood cell (p = ) counts. Similarly, IDH mutation was not correlated with changes in peripheral red blood cell (p = ) or white blood cell (p = ) counts during the course of treatment. Association of Changes in White Blood Cell Counts With OS The Kaplan-Meier estimated 2-year survival rate for patients with a decrease in white blood cell counts from baseline was 58% and that for patients with an increase relative to baseline was 25% (p = ; Fig. 1). Patients with decreases in white blood cell counts had a median OS of 850 days (95% CI days) compared with 627 days (95% CI days) for those with increases in white blood cell counts from baseline. We found no significant differences in OS between subgroups of patients with decreased white blood cell counts during treatment, when the data were stratified by quartile or median decrease. Discussion We here demonstrate that treatment-associated myelosuppression, as manifested by a decrease in circulating white blood cell counts from baseline during adjuvant 134
4 Bone marrow response as a potential biomarker TABLE 1. Patient blood counts Hematology Baseline Platelets ( 10 9 /L) Red blood cells ( /L) White blood cells ( 10 9 /L) Eosinophils ( 10 9 /L) Basophils ( 10 9 /L) Lymphocytes ( 10 9 /L) Neutrophils ( 10 9 /L) Monocytes ( 10 9 /L) 6-mo adjuvant TMZ* Platelets ( 10 9 /L) Red blood cells ( /L) White blood cells ( 10 9 /L) Eosinophils ( 10 9 /L) Basophils ( 10 9 /L) Lymphocytes ( 10 9 /L) Neutrophils ( 10 9 /L) Monocytes ( 10 9 /L) Value (97.59) (0.43) (3.29) (0.11) (0.03) (0.73) (2.90) (0.24) (65.76) (0.45) (2.50) (0.10) (0.02) (0.41) (2.21) (0.18) * Blood counts obtained at the time of the 6th monthly cycle of TMZ treatment. TABLE 2. Summary of patient characteristics Characteristic Sex Male Female Age at diagnosis, yrs OS, days PFS, days Genetic mutation EGFR MGMT IDH Steroid use Deceased Values represent n (%) unless otherwise indicated. Value 54 (63%) 32 (37%) (12.55) (476.37) (487.02) (50.00%) 39 (54.17%) 6 (8.96%) 62 (72.09%) 67 (77.91%) TMZ therapy, might serve as a potential prognostic marker for clinical outcomes in patients with GBM. Our serial assessment of peripheral blood counts and additional laboratory and radiographic data found that a decrease in white blood cells from baseline during adjuvant TMZ therapy predicts significantly improved OS. Our institutional survival data for patients with decreases in white blood cells compares favorably with data from the original EORTC/NCIC trial, which reported a median survival of 14.6 months and a 2-year survival rate of 26.5% for patients receiving radiotherapy plus TMZ. 16 The present findings are consistent with findings of previous studies demonstrating an association of MGMT promoter methylation and IDH1 mutation with improved clinical outcomes. 3,5,6,17,21 Interestingly, we found that MGMT promoter methylation and IDH mutation did not correlate with changes in white blood cell counts, suggesting that these changes may serve as an independent prognostic factor. Despite these robust findings, our study is limited by its modest sample size and retrospective nature. Nevertheless, our exploratory analysis of hematological parameters identified that treatment-related changes in white blood cell counts are associated with OS, with decreases in white blood cell counts from baseline serving as a biomarker for improved OS. This association was maintained on multivariate analysis, even after controlling for other known prognostic variables, including age at the time of diagnosis, steroid use, EGFR amplification status, and MGMT promoter methylation status. On subgroup analysis, decreases in white blood cell counts from baseline maintained a strong association with improved OS regardless of whether a patient used steroids during TMZ therapy. Notably, an increase in white blood cell counts from baseline was also considered an important biomarker for worse OS, suggesting that changes in white blood cell counts play an 135
5 E. J. Vaios et al. TABLE 3. Univariate analysis for OS Covariate HR 95% CI p Value* Sex Male Female Age Genetic mutations EGFR MGMT IDH Percent change in Platelets Red blood cells White blood cells Eosinophils Basophils Lymphocytes Neutrophils Monocytes Steroids Used Not used * Based on log-rank test important biological role in the tumor microenvironment independent of chemotherapy. We were unable to identify an association between changes in the peripheral platelet count and clinical outcomes, as described by Williams et al. 22 This finding suggests that decreases in white blood cell counts, rather than general bone marrow suppression, might be a predictor of improved OS. However, we did not observe a statistically significant association between white blood cell changes and PFS in our multivariate model, when controlling for steroid use and other markers that were significant on univariate analysis (Supplemental Data). Our findings, however, indicate that patient age and MGMT promoter methylation are important predictors of PFS. Changes in neutrophils were also significantly associated with OS and PFS, with neutrophil increases from baseline predicting worse outcomes. However, given the association of neutrophil counts with medications (e.g., steroid use), infections, and environmental factors, these findings remain more challenging to interpret. Neutrophil counts were likely confounded by steroid use, perhaps indicative of more aggressive tumor growth necessitating steroid administration for the management of edema. Consistent with the literature, our study found that steroid use was associated with elevated neutrophil counts and worse outcomes. In patients who did not receive steroids, we did not observe an association between neutrophil counts and OS. Therefore, this hematological parameter was excluded from our multivariate analysis. The observed relationship between a decrease in white blood cell counts and clinical outcomes is possibly due to higher in vivo drug concentrations of TMZ, resulting from differences in drug metabolism. TMZ activity is dose and schedule dependent and induces cytotoxicity primarily by TABLE 4. Multivariate analysis for OS Covariate HR 95% CI p Value* Age < MGMT < EGFR White blood cells Increase Decrease Red blood cells Increase Decrease Steroids Used Not used IDH was excluded due to inadequate sample size. * Based on log-rank test causing O 6 -meg lesions, which deplete the repair enzyme MGMT, leading to double-strand DNA breaks and tumor cell apoptosis. 7,13,14,25 TMZ is administered orally and has a half-life of 1.8 hours, reaching concentrations in the CSF that are 30% 40% of plasma concentrations. The clinical efficacy of TMZ and its active metabolite depends on MGMT activity; the integrity of the mismatch repair system, which recognizes O 6 -meg lesions in template DNA strands; and function of the base excision repair system, which corrects highly lethal N 3 -mea lesions via poly (ADP-ribose) polymerase. 9,10,20 There are no guidelines for dose adjustment based on the tumor genetic signature or in the context of severe renal or hepatic impairment. Since FIG. 1. Kaplan-Meier analysis of OS in patients stratified by increase (dotted line) or decrease (solid line) in white blood cell counts from baseline. A significant survival benefit is noted for patients with a decrease in white blood cells relative to baseline (log-rank p = ). 136
6 Bone marrow response as a potential biomarker current dosing guidelines do not factor interpatient differences in resistance mechanisms or patient-specific drug metabolism, it is possible that some patients are treated subtherapeutically. Given the routine and reliable assessment of peripheral blood counts in GBM patients receiving conventional therapies, white blood cell counts could serve as a valuable biomarker of treatment response and for predicting clinical outcomes. Future prospective studies should address whether blood cell counts could serve as a correlate biomarker for in vivo TMZ levels and drug activity as well as a predictor of clinical outcomes, which in turn could help to optimize dosing and scheduling of chemotherapy by accounting for variability in drug metabolism. Conclusions We report a temporal relationship between changes in peripheral white blood cell counts during adjuvant TMZ treatment and clinical outcomes. Specifically, depression of white blood cell counts appears to be an independent prognostic factor and was associated with improved OS. This relationship may be a reflection of plasma TMZ levels and, in time, may serve as a surrogate marker of therapeutic efficacy. These findings warrant further investigation in prospective studies, including correlations with the degree of change in white blood cell counts and pharmacokinetics of TMZ in individual patients. It also remains unclear whether treatment-associated changes in white blood cell counts correlate with drug-induced antitumor activity or represent an independent factor of the altered local and systemic tumor environment. Acknowledgments This work was supported by the 2015 Neurosurgical Research and Education Foundation (NREF) Medical Student Summer Research Fellowship (Eugene J. Vaios) and the Harvard Medical School Scholars in Medicine Office (Eugene J. Vaios). Jorg Dietrich received support from the American Academy of Neurology, the American Cancer Society, and generous gifts from the family foundations of Bryan Lockwood, Ronald Tawil, and Sheila McPhee. References 1. Bastien JI, McNeill KA, Fine HA: Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121: , Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF: Pros and cons of current brain tumor imaging. Neuro Oncol 16 (Suppl 7):vii2 vii11, Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al: Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: , Fujita T, Wakatabe Y, Matsumoto K, Tabata K, Yoshida K, Iwamura M: Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma. Anticancer Res 34: , Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: , Idbaih A, Omuro A, Ducray F, Hoang-Xuan K: Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 19: , Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99: , Lonardi S, Tosoni A, Brandes AA: Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 31:79 89, Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56: , Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, et al: The selective poly(adp-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6: , Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: , Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: , Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35 61, Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O 6 - methylguanine. Oncogene 26: , Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: , Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: , Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, et al: Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 120: , Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J: Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10:14 26, Thomas AA, Brennan CW, DeAngelis LM, Omuro AM: Emerging therapies for glioblastoma. JAMA Neurol 71: , Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64: , von Deimling A, Korshunov A, Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74 87, Williams M, Liu ZW, Woolf D, Hargreaves S, Michalarea V, Menashy R, et al: Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J Cancer Res Clin Oncol 138: , Wilson TA, Karajannis MA, Harter DH: Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5:64,
7 E. J. Vaios et al. 24. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, et al: Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res 17: , Ziegler DS, Kung AL, Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26: , 2008 Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author Contributions Conception and design: Vaios, Nahed, Dietrich. Acquisition of data: Vaios. Analysis and interpretation of data: Vaios, Nahed, Muzikansky, Dietrich. Drafting the article: Vaios. Critically revising the article: Vaios, Nahed, Fathi, Dietrich. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Vaios. Statistical analysis: Vaios, Muzikansky. Administrative/technical/material support: Nahed, Dietrich. Study supervision: Nahed, Dietrich. Supplemental Information Online-Only Content Supplemental material is available with the online version of the article. Supplemental Tables 1A and B. suppl/0.3171/ jns Correspondence Eugene John Vaios, Vanderbilt Hall Box 099, 107 Ave. Louis Pasteur, Boston, MA eugene_vaios@hms.harvard. edu. 138
Scottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationTreatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
More information3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationEpidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis
Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationTemozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationBrain Tumors: Radiologic Perspective
Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the
More informationNCCP Chemotherapy Regimen. Temozolomide with Radiotherapy (RT) and Adjuvant Therapy
Temozolomide with Radiotherapy (RT) INDICATIONS FOR USE: Regimen Code ISMO Contributor: Prof Maccon Keane Page 1 of 6 *Reimbursement Status INDICATION ICD10 Adult patients with newly-diagnosed glioblastoma
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationThis study was designed to evaluate an online prognosis
Neuro-Oncology 15(8):1074 1078, 2013. doi:10.1093/neuonc/not033 Advance Access publication March 29, 2013 NEURO-ONCOLOGY Can the prognosis of individual patients with glioblastoma be predicted using an
More informationPrognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationBevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma
Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationTreatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study
ORIGINAL ARTICLE Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study E.R. Morgan md,* A. Norman md, K. Laing md, and M.D. Seal md ABSTRACT Purpose
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationSee the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,
More informationInterferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas
MOLECULAR AND CLINICAL ONCOLOGY 3: 909-913, 2015 Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas HIROSHI KAWAJI, TSUTOMU TOKUYAMA, TOMOHIRO YAMASAKI,
More informationTo analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma
To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma R. Zalazar, M. Páramo, M. Hernández, P. Domínguez, J.Etxano, P.García Barquín, H.Quiceno Arias,
More informationLow grade glioma: a journey towards a cure
Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationPredictive Biomarkers in GBM
Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationWhat yield in the last decade about Molecular Diagnostics in Neuro
What yield in the last decade about Molecular Diagnostics in Neuro Oncology? Raphael Salles S.Medeiros Neuropathologist at HC FMUSP Clinical Research Project Manager at Oncology department at Hospital
More informationConcurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme
Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationUniversity of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationComputer-extracted MR imaging features are associated with survival in glioblastoma patients
Computer-extracted MR imaging features are associated with survival in glioblastoma patients Maciej A. Mazurowski, Ph.D. 1, Jing Zhang, Ph.D. 1, Katherine B. Peters, M.D., Ph.D. 2, Hasan Hobbs, M.D. 1
More informationBevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma
Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma Design and analysis of single-arm Phase II clinical trial
More informationRetrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page 4551-4555 Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationChemotherapy in malignant brain tumors
Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma
More informationEarly postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials
J Neurooncol (2017) 132:249 254 DOI 10.1007/s11060-016-2362-z CLINICAL STUDY Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials Andreas Merkel
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationCNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician
BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact
More informationTemozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience
Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,
More informationElderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy
Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Christine N Chang-Halpenny, MD; Jekwon Yeh, MD; Winston W Lien, MD
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationpissn , eissn Open Access Original Article
pissn 1598-2998, eissn 25-9256 Original Article https://doi.org/1143/crt.215.473 Open Access Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
More informationORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,
More informationRINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationDouglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationCHMP Type II variation assessment report
26 January 2017 EMA/CHMP/59238/2017 Invented name: Avastin International non-proprietary name: bevacizumab Procedure No. EMEA/H/C/000582/II/0093 Marketing authorisation holder (MAH): Roche Registration
More informationSurvival Analysis of Glioblastoma Multiforme
DOI:10.22034/APJCP.2018.19.9.2613 RESEARCH ARTICLE Editorial Process: Submission:04/24/2018 Acceptance:08/19/2018 Supapan Witthayanuwat, Montien Pesee*, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul,
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationThe Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR) on Survival of Patients with Glioblastoma Multiforme (GBM): A Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR) on Survival
More informationClinical significance of FBXO17 gene expression in high-grade glioma
Du et al. BMC Cancer (2018) 18:773 https://doi.org/10.1186/s12885-018-4680-3 RESEARCH ARTICLE Open Access Clinical significance of FBXO17 gene expression in high-grade glioma Di Du 1, Jian Yuan 2, Wencai
More informationRelated Policies None
Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationThe Response to Chemo Radiation. Therapy in Unresectable Glioblastoma
Research Article imedpub Journals http://www.imedpub.com Journal of Clinical Epigenetics DOI: 10.21767/2472-1158.100054 Abstract The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationFACT SHEET. About Optune
About Optune Optune is the Tumor Treating Fields (TTFields) delivery system that is approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with glioblastoma.
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
original article MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Monika E. Hegi, Ph.D., Annie-Claire Diserens, M.Sc., Thierry Gorlia, M.Sc., Marie-France Hamou, Nicolas de Tribolet, M.D.,
More informationHematologic Toxicity of Temozolomide and Radiation in Glioblastoma Patients Correlation with Clinicopathological Factors
Clinical Medicine Journal Vol. 1, No. 2, 2015, pp. 63-69 http://www.aiscience.org/journal/cmj Hematologic Toxicity of Temozolomide and Radiation in Glioblastoma Patients Correlation with Clinicopathological
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationProtocol Abstract and Schema
Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy
More informationJosh is JB s brother and caregiver.
PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationDose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationEpidemiology and Semiology of Tumor-based Epilepsy December 2, 2012
Epidemiology and Semiology of Tumor-based Epilepsy December 2, 2012 Charles J. Vecht, MD, PhD Medical Center The Hague SEIN Epilepsy Foundation, The Netherlands CHU Pitié-Salpêtrière, Paris, France American
More informationPublisher s version PDF Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Publisher s version PDF Faculty of Biology and Medicine Publication Title: MGMT gene silencing and benefit from temozolomide in glioblastoma. Authors:
More informationNon-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma. Multiforme Treated with Bevacizumab
Research Article imedpub Journals www.imedpub.com Archives in Cancer Research DOI: 10.21767/2254-6081.100177 Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated
More informationLimited role for extended maintenance temozolomide for newly diagnosed glioblastoma
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Limited role for extended maintenance temozolomide for newly diagnosed
More informationDepartment of Medical Oncology, National Cancer Institute of Aviano, Aviano (PN) Italy 3
WCRJ 2014; 1 (4): e401 RADIOCHEMOTHERAPY FOR UNRESECTABLE GLIOBLASTOMA MULTIFORME: A MONO- INSTITUTIONAL EXPERIENCE M. COLELLA 1, F. FIORICA 1, P. API 1, A. STEFANELLI 1, B. URBINI 2, A. SGUALDO 1, D.
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationIs there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma?
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma? Juan M Sepúlveda Sánchez Neurooncology Unit Hospital Universitario 12 de Octubre. Madrid Topics 1.-EGFR pathway as a potential
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationLynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3
Ashby et al. World Journal of Surgical Oncology (2016) 14:225 DOI 10.1186/s12957-016-0975-5 REVIEW Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide
More information